Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Mar 31 04:00PM ET
6.90
Dollar change
+0.13
Percentage change
1.92
%
IndexRUT P/E65.53 EPS (ttm)0.11 Insider Own36.68% Shs Outstand77.33M Perf Week-9.21%
Market Cap536.48M Forward P/E33.66 EPS next Y0.20 Insider Trans-0.12% Shs Float49.23M Perf Month22.34%
Income8.55M PEG2.28 EPS next Q0.02 Inst Own29.21% Short Float3.84% Perf Quarter22.99%
Sales99.60M P/S5.39 EPS this Y18.18% Inst Trans26.13% Short Ratio2.35 Perf Half Y82.54%
Book/sh0.60 P/B11.58 EPS next Y57.69% ROA13.88% Short Interest1.89M Perf Year88.01%
Cash/sh0.57 P/C12.01 EPS next 5Y28.79% ROE22.94% 52W Range2.31 - 9.18 Perf YTD30.07%
Dividend Est.- P/FCF45.12 EPS past 5Y- ROI17.91% 52W High-24.84% Beta2.18
Dividend TTM- Quick Ratio3.06 Sales past 5Y16.76% Gross Margin61.84% 52W Low199.35% ATR (14)0.45
Dividend Ex-Date- Current Ratio3.57 EPS Y/Y TTM268.89% Oper. Margin10.57% RSI (14)46.78 Volatility5.65% 7.56%
Employees104 Debt/Eq0.06 Sales Y/Y TTM19.18% Profit Margin8.58% Recom1.00 Target Price9.78
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q5760.00% Payout0.00% Rel Volume1.21 Prev Close6.77
Sales Surprise8.78% EPS Surprise300.00% Sales Q/Q37.41% EarningsMar 04 AMC Avg Volume806.22K Price6.90
SMA20-8.90% SMA507.01% SMA20043.42% Trades Volume975,116 Change1.92%
Date Action Analyst Rating Change Price Target Change
Aug-16-22Downgrade Oppenheimer Outperform → Perform
Aug-11-22Downgrade B. Riley Securities Buy → Neutral $6 → $2.40
Mar-08-22Initiated ROTH Capital Buy $7
Oct-16-19Initiated Oppenheimer Outperform $6
Feb-14-19Initiated B. Riley FBR Buy $7
Nov-27-17Resumed H.C. Wainwright Buy $6 → $8
Sep-25-17Initiated Ladenburg Thalmann Buy $7
Jan-03-17Initiated Rodman & Renshaw Buy $6
Mar-20-25 08:34AM
Mar-19-25 08:34AM
Mar-13-25 08:34AM
Mar-11-25 04:04PM
Mar-05-25 11:11AM
02:10AM Loading…
02:10AM
Mar-04-25 05:15PM
04:13PM
04:02PM
Mar-03-25 07:14AM
Feb-25-25 04:07PM
Jan-06-25 08:32AM
Dec-03-24 08:34AM
Nov-22-24 09:15AM
Nov-14-24 08:32AM
12:00PM Loading…
Nov-08-24 12:00PM
Nov-07-24 08:32AM
Nov-05-24 09:15AM
Nov-01-24 11:02AM
Oct-31-24 05:15PM
04:09PM
04:04PM
Oct-30-24 09:20AM
Oct-28-24 08:32AM
Oct-24-24 08:32AM
Oct-23-24 08:34AM
Oct-18-24 09:40AM
Oct-15-24 08:32AM
Oct-09-24 05:18PM
Sep-26-24 04:12PM
09:40AM Loading…
09:40AM
Sep-20-24 08:32AM
Sep-10-24 08:32AM
Sep-09-24 08:34AM
Aug-23-24 08:34AM
Aug-19-24 08:32AM
Aug-07-24 06:25PM
05:25PM
04:04PM
Aug-05-24 08:32AM
Jul-24-24 08:34AM
Jul-23-24 08:32AM
Jul-22-24 08:34AM
Jul-16-24 08:34AM
Jul-01-24 08:32AM
Jun-24-24 08:32AM
Jun-13-24 08:32AM
Jun-10-24 09:45AM
Jun-07-24 08:34AM
Jun-04-24 08:32AM
May-23-24 08:34AM
May-22-24 08:32AM
May-10-24 03:22PM
May-09-24 02:34PM
07:17AM
03:42AM
May-08-24 08:58PM
05:04PM
04:04PM
Apr-30-24 08:32AM
Apr-25-24 08:34AM
Apr-24-24 08:34AM
Apr-23-24 08:32AM
Mar-26-24 08:32AM
Mar-07-24 01:59PM
10:37AM
06:27AM
Mar-06-24 09:53PM
04:04PM
Feb-21-24 08:32AM
Feb-05-24 08:32AM
Jan-26-24 04:08PM
Dec-20-23 09:04AM
Dec-12-23 10:30AM
Nov-30-23 08:34AM
Nov-15-23 08:32AM
Nov-10-23 12:54PM
Nov-09-23 08:32AM
Nov-08-23 06:33PM
04:48PM
04:02PM
Nov-01-23 08:34AM
Oct-31-23 08:34AM
Oct-26-23 08:32AM
Oct-02-23 08:32AM
Aug-24-23 08:32AM
Aug-12-23 09:04AM
Aug-10-23 10:38AM
Aug-09-23 05:40PM
04:37PM
04:02PM
Aug-08-23 08:34AM
Aug-07-23 08:32AM
Aug-02-23 08:02AM
Jul-18-23 08:32AM
Jun-16-23 08:32AM
Jun-08-23 08:19AM
May-30-23 08:34AM
May-11-23 08:34AM
May-10-23 05:35PM
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lopez Carlos LuisSVP, General CounselMar 07 '25Buy7.862732,1462,251Mar 10 08:11 AM
Jaksch Frank L JrDirectorDec 13 '24Option Exercise3.6650,001183,004281,340Dec 13 07:12 PM
Jaksch Frank L JrDirectorDec 13 '24Sale6.1937,161229,956244,179Dec 13 07:12 PM
Frank Jaksch Jr.affiliateDec 13 '24Proposed Sale6.1937,161229,961Dec 13 01:54 PM
Pamir OzanChief Financial OfficerNov 22 '24Buy7.362,90721,3972,907Nov 25 07:28 AM
Patrick KristinDirectorAug 23 '24Option Exercise1.6723,00038,32023,000Aug 26 07:06 PM
Patrick KristinDirectorAug 23 '24Sale3.5723,00082,1100Aug 26 07:06 PM
Kristin PatrickaffiliateAug 23 '24Proposed Sale3.6923,00084,810Aug 23 11:52 AM